Biomarkers associated with response to tebotelimab
NSCLC, TNBC, tumor
TUMOR, NSCLC
To determine potential relationships of clinical response to tebotelimab (exploratory endpoint), IHC analyses of tumor tissue were performed to evaluate PD-L1 (a universally employed IHC biomarker for PD-1-targeted therapies) and LAG-3 expression. Seven of the eight confirmed responders within the EOC, TNBC and NSCLC expansion cohorts had LAG-3 expression at baseline, and half (